News & Media
Newsroom
SK life science Initiates Phase 3 Clinical Trial of Carisbamate for Lennox-Gastaut Syndrome
1.6.2022
Full Release
SK Biopharmaceuticals Enters into Licensing Agreement with Endo for Cenobamate in Canada
12.23.2021
Full Release
SK life science Presents Long-Term Data of XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset Seizures at the American Epilepsy Society 2021 Annual Meeting
12.3.2021
Full Release
Welcome to the news and information center for SK Life Science, Inc.
To learn more about SK Life Science, please download our corporate fact sheet
For more information about epilepsy, please download this infographic
For more information about Lennox-Gastaut syndrome, please download this fact sheet
SK Life Science at a Glance
Headquarters Location: Paramus, NJ
R&D Begins: 1993
Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, CO., LTD, and both are a part of SK Group
Number of Employees: 200+ Employees
Disease Category Focus: CNS Disorders and Oncology
Pipeline: 8 compounds under clinical development